Canaccord reported on Illumina (NASDAQ:ILMN), scaling down its target to $136.00 earlier today
- Updated: October 10, 2016
Displaying a price of $184.85, Illumina (NASDAQ:ILMN) traded 0.00% even on the day. With the last stock price close up 18.07% from the 200-day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. ILMN has recorded a 50-day moving average of $175.01 and a 200-day moving average of $156.56. Volume of trade was down over the average, with 2,633 shares of ILMN changing hands under the typical 1,026,110
Illumina (NASDAQ:ILMN) had its price target dropped to $136.00 by Canaccord in a report issued Tuesday October 11, 2016. The reduced price target implies a potential downside of -0.26% based on the company's last stock close price.
Previously on 10/03/2016, Vetr Inc. reported on Illumina (NASDAQ:ILMN) raised the target price from $0.00 to $198.61. At the time, this suggested an upside of 0.09%.
Illumina has P/E ratio of 63.30 with a 52 week low of $127.10 and a 52 week high of $196.47 and has a market capitalization of $0.
In addition to Canaccord reporting its target price, a total of 19 brokers have issued a research note on ILMN. The one year target is $154.53 with four analysts rating the stock a strong buy, 4 brokerages rating the company a buy, fifteen firms rating the stock a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.
General Company Details For Illumina (NASDAQ:ILMN)
Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.